Overview / Abstract: |
Program Overview The management of progressing fibrotic pulmonary disease continues to evolve and guidelines are challenged to stay abreast of, and to reflect, advances from recent clinical studies or drug approvals. Clinicians need to be aware of this challenging landscape to develop treatment plans that are current and that help patients to achieve optimal outcomes. In this podcast, Drs. Zibrak and Saketkoo will review the evidence supporting the use of antifibrotic agents, specifically nintedanib and pirfenidone in patients with IPF and the emerging evidence that these drugs may be useful in SSc-ILD. What is the role of currently approved antifibrotics in the treatment of PF-ILD? Learning Objectives Upon completion of this activity, participants should be better able to: Evaluate the role of currently available antifibrotic agents in the treatment of patients with pulmonary fibrosis associated with IPF and SSc-ILD. |
Expiration |
Aug 26, 2020 |
Discipline(s) |
Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Podcast |
Credits / Hours |
.5 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Joseph D. Zibrak, MD Associate Professor of Medicine Associate Professor of Medicine |
Activity Specialities / Related Topics |
Acute Care, Critical Care / Intensive Care, Emergency Medicine, Geriatrics / LTC, Oncology / Cancer / Radiation Therapy, Pathology, Pharmacology, Pulmonary Medicine / COPD, Radiology / Imagery / Nuclear Medicine |
Sponsors / Supporters / Grant Providers |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Keywords / Search Terms |
Relias LLC ild, lung disease, ipf Free CE CME |